NRIX · Nurix Therapeutics Inc
United States · RS rating 94 · As of 2026-11-03
| Price | 25.82 USD |
|---|---|
| 1-day change | +0.5% |
| RS rating (overall / 1M / 3M / 12M) | 94 / 86 / 73 / 94 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 45 / 55 / 42 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +3.7% |
| Sales growth Q/Q | -54.0% |
| Distance from 52-week high | +7.1% |
| Market cap (USD) | $1.7B |